---
title: "Alterity Therapeutics Issues 8.4 Million Shares Under Underwriting Deal"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298249430.md"
description: "Alterity Therapeutics (AU:ATH) issued 8.4 million fully paid ordinary shares to MST Financial Services and sub-underwriters under a previously announced agreement tied to ATHO listed options. The issuance was made without a prospectus under Corporations Act cleansing provisions, ensuring compliance with continuous disclosure obligations. This move supports the company's capital needs while maintaining regulatory adherence."
datetime: "2026-09-08T02:07:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298249430.md)
  - [en](https://longbridge.com/en/news/298249430.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298249430.md)
generator: "portal-rs"
---

# Alterity Therapeutics Issues 8.4 Million Shares Under Underwriting Deal

Alterity Therapeutics ( (AU:ATH) ) has shared an update.

Alterity Therapeutics Limited, an ASX-listed Australian biopharmaceutical company, has issued 8,400,000 fully paid ordinary shares to MST Financial Services and sub-underwriters under a previously announced underwriting agreement tied to its ATHO class of listed options. The issuance reflects the company’s use of structured equity instruments and underwriting support to manage its capital needs within the framework of Australia’s corporate disclosure rules.

The company has confirmed that the new shares were issued without a prospectus under the Corporations Act’s cleansing provisions, while stating it remains compliant with key financial reporting and continuous disclosure obligations and has no excluded information requiring disclosure. This notice reassures investors and underwriters that the additional share issuance aligns with regulatory requirements, supporting market confidence in Alterity’s governance and capital-market practices.

The most recent analyst rating on (AU:ATH) stock is a Buy  
 with a A$0.95 price target.  
 To see the full list of analyst forecasts on Alterity Therapeutics stock,  
 see the AU:ATH Stock Forecast page. 

**More about Alterity Therapeutics**

Alterity Therapeutics Limited is an Australian biopharmaceutical company listed on the ASX under the ticker ATH, focused on developing novel therapies, with its securities including fully paid ordinary shares and various classes of listed options. The company operates within the life sciences sector and is subject to Australian corporate and continuous disclosure regulations that govern its capital markets activities.

Alterity’s capital structure includes ATHO listed options, which are exercisable at a set price and managed through underwriting arrangements with financial services firms. These mechanisms support the company’s access to equity funding while maintaining compliance with relevant provisions of the Corporations Act and ASX reporting requirements.

**Average Trading Volume:** 288,476

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** A$110.4M

Learn more about ATH stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [ATHE.US](https://longbridge.com/en/quote/ATHE.US.md)
- [ATH.AU](https://longbridge.com/en/quote/ATH.AU.md)

## Related News & Research

- [Insider Move at Biotech Firm Sparks Fresh Investor Interest](https://longbridge.com/en/news/298398581.md)
- [Alterity Therapeutics Seeks Quotation for New ASX Shares](https://longbridge.com/en/news/299120002.md)
- [Alterity Therapeutics issues 8,400,000 shares tied to exercised options at A$ 0.5 each](https://longbridge.com/en/news/298298137.md)
- [Alterity Therapeutics issues shares from exercise of listed options at A$0.5 each](https://longbridge.com/en/news/297504784.md)
- [Alterity Therapeutics Granted ATH434 Patent to Treat Neurodegenerative Diseases](https://longbridge.com/en/news/295601215.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**